Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Tolerance to self-antigens prevents the elimination of cancer by the immune system 1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27+CD45RO-CD8+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27+PD-1-CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the environment and host of supplied live cells play a significant role in the survivability, durability, and maintenance of beneficial cell phenotypes.330”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [330]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Higher degrees of expansion (Cmax) and/or longer durations of expansion (area under the curve, AUC) of CAR-T cells in patients have been identified as biomarkers associated with positive clinical responses [34, 35].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [35]
In the citing paper
“Identified factors that affect the efficacy of CAR T-cell therapy include the quality of circulating T cells used for manufacturing, homeostatic cytokine levels at the end of lymphodepleting (LD) chemotherapy, and CAR T-cell expansion.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [3]
In the citing paper
“For example, CAR T-cell fitness is related to the quality of the starting T cells obtained by apheresis, which may be affected by tumor and prior therapy.3,39,40”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Self-citationTelomere measurement by quantitative PCR
Cawthon, R. M. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.10.e47 · Cited by 3,487
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citation
Cited by
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
Self-citationAnti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
“Stringent complete response 0 5 (63) 3 (38) 4 (36) 0 12 (40) 12 (36)”
Self-citationEngineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Metadata
- Authors
- Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., Pequignot, E., Ambrose, D. E., Zhang, C., Wilcox, N., Bedoya, F., Dorfmeier, C., Chen, F., Tian, L., Parakandi, H., Gupta, M., Young, R. M., Johnson, F. B., Kulikovskaya, I., Liu, L., Xu, J., Kassim, S. H., Davis, M. M., Levine, B. L., Frey, N. V., Siegel, D. L., Huang, A. C., Wherry, E. J., Bitter, H., Brogdon, J. L., Porter, D. L., June, C. H., & Melenhorst, J. J.
- Affiliations
- University of Pennsylvania (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Melenhorst, J. Joseph
- ORCID
- Fraietta, Joseph A.
- Lacey, Simon F.
- Orlando, Elena J.
- Pruteanu-Malinici, Iulian
- Gohil, Mercy
- Lundh, Stefan
- Boesteanu, Alina C.
- Wang, Yan
- O’Connor, Roddy S.
- Hwang, Wei-Ting
- Zhang, Changfeng
- Wilcox, Nicholas
- Tian, Lifeng
- Gupta, Minnal
- Young, Regina M.
- Johnson, F. Brad
- Kulikovskaya, Irina
- Xu, Jun
- Kassim, Sadik H.
- Levine, Bruce L.
- Frey, Noelle V.
- Huang, Alexander C.
- Wherry, E. John
- Bitter, Hans
- Brogdon, Jennifer L.
- Porter, David L.
- June, Carl H.
- Melenhorst, J. Joseph
- Venue
- Nature Medicine
- Published
- 2018-04-30
- Volume
- 24
- Issue
- 5
- Pages
- 563-571
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6117613
- OpenAlex
- W2801641802
- Cited by
- 1,785
- References
- 57
- Citations by year
- 2026: 218 · 2025: 223 · 2024: 248 · 2023: 231 · 2022: 248 · 2021: 229 · 2020: 206 · 2019: 138 · 2018: 41
- FWCI
- 57.66
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-02-05)
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (T32CA009140, R01CA165206, P01CA214278, P30CA016520)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- chronic lymphocytic leukemia, CAR T-cell therapy, CD19 chimeric antigen receptor, treatment response, resistance mechanisms, IL-6/STAT3 signaling, IL-6 receptor, tumor immune tolerance, gene expression profiling, predictive biomarkers, T cell exhaustion, CD8+ T cells
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Female, Male, Transcription, Genetic, Leukemia, Lymphocytic, Chronic, B-Cell, Interleukin-6, Immunotherapy, Adoptive, Treatment Outcome, Antigens, CD19, STAT3 Transcription Factor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1038/s41591-018-0010-1
- The paper
- Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., Pequignot, E., Ambrose, D. E., Zhang, C., Wilcox, N., Bedoya, F., Dorfmeier, C., Chen, F., Tian, L., Parakandi, H., . . . Melenhorst, J. J. (2018). Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine. https://doi.org/10.1038/s41591-018-0010-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.